Searched for
RANBAXY PHARMA
After 50 hearings, court reserves judgement in Daiichi-Fortis caseThe Delhi High Court has reserved its judgment in a significant arbitration case. Japanese drug maker Daiichi Sankyo is seeking to enforce ...- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- 4 Ranbaxy execs quit as Sun Pharma wraps up rejigSun Pharma MD Dilip Shanghvi had told TOI the company will "use and nurture the talent" of Ranbaxy, and "is not considering any job cuts".
- Aurobindo Pharma appoints former Ranbaxy senior executive Sanjeev Dani as COOAurobindo Pharma has appointed Sanjeev Dani, former senior executive with Ranbaxy Laboratories, as chief operating officer and head of form...
- Sun-Ranbaxy $4 billion merger completedSun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.
- Sun Pharma executives bag top slots in company after Ranbaxy mergerMost executives from Ranbaxy's earlier team have already left the company in past one year.
- Ranbaxy stock up 50% post deal with Sun Pharma; co grabs 13% market share after Diovan’s launchUnder the terms of the acquisition, for every five shares held in Ranbaxy, shareholders are going to receive four of Sun Pharma.
- Andhra Pradesh High Court puts on hold Sun-Ranbaxy deal till insider trade verdictShares of Ranbaxy, which is majority-owned by Japan’s Daiichi-Sankyo, saw an unusual increase in price and turnover during six trading days...
- Sun Pharma denies insider trading charges in Ranbaxy dealSun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...
- Buy Sun Pharma shares through RanbaxyAn investor who is really confident that the deal will go through can buy Ranbaxy shares and pocket the difference when the merger is compl...
- Merger with Sun Pharma will spell the end of Ranbaxy brand, but a new dawn beckonsSun Pharma may not have to face surprises emanating from Ranbaxy. There is every likelihood that brand Ranbaxy will see a sunset clause whe...
- Sun Pharma to buy Ranbaxy in $3.2 bn deal: HighlightsSun Pharmaceutical Industries said that it will buy generic drug maker Ranbaxy Laboratories, has hit regulatory snags in its key US market ...
- Ranbaxy episode to hit drugs carrying ‘India’ label; tough to secure new contractsDrug makers worry that the Ranbaxy example puts the entire Indian industry under the bracket of “dirty” manufacturers.
- Ranbaxy sell-off may price open more dealsThe deal may prompt other Indian promoters to divest their stake at the right place and at the right time, instead of clinging on for emoti...
- DS Brar happy, sees pact as trendsetterThe man credited for converting Ranbaxy into an Indian MNC, Mr Brar, today feels the Ranbaxy-Daiichi Sankyo deal is good for all the stake ...
- Cipla edges Ranbaxy in India marketRanbaxy has been eyeing an acquisition in the domestic market for a while now.
Load More
